The forecast for anxiolytic medicine sales in Canada shows stability in per capita expenditure. Following an increase in 2024, maintaining the level of 2.8 USD, the market stabilizes at 2.7 USD from 2025 to 2028. This indicates a negligible year-on-year variation, reflecting a plateau in sales after an initial rise. Without 2023 data, it's difficult to compute exact growth rates. Nevertheless, the Compound Annual Growth Rate (CAGR) for the forecasted period suggests minimal change.

Future trends to watch for:

Potential impacts of healthcare policy changes on drug pricing.
Trends in mental health awareness that could drive demand.
Influence of technological advancements and telemedicine on prescription practices.